Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aim: To assess the possible risk of acute kidney injury (AKI) with the use of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐i) as well as changes in estimated glomerular filtration rate (eGFR), hospitalizations and mortality in a real‐world setting. Materials and methods: Included in this historical cohort study were patients with type 2 diabetes in a large health organization in Israel who initiated therapy with SGLT2‐i or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) during 1 April 2015 to 30 June 2017. We collected data on serum creatinine measurements taken between 180 days prior to and 24 weeks after therapy initiation. Study endpoints included ≥30% reduction in eGFR, hospitalization with AKI, any hospitalization and all‐cause mortality. Results: Overall 6418 and 5604 patients initiated SGLT2‐i and DPP‐4i, respectively. Baseline mean (SD) eGFR was higher among the SGLT2‐i group compared with the DPP‐4i group (88.3 [17.4] and 82.8 [23.7], respectively) but were similar when stratifying by chronic kidney disease (CKD) stages. The adjusted odds ratio (OR) (95% confidence interval [CI]) for ≥30% reduction in eGFR with SGLT2‐i versus DPP4‐i was 0.70 (0.49‐1.00) and ORs ranged from 1.97 (0.62‐6.26) to 0.45 (0.21‐0.99) in patients with baseline eGFR 30 to 45 and ≥90 mL/min/1.73 m 2 , respectively. Risks of AKI (OR = 0.47, 95% CI 0.27‐0.80), hospitalization (OR = 0.66, 95% CI 0.56‐0.78) or all‐cause mortality (OR = 0.43, 95% CI 0.20‐0.95) were lower in patients initiating SGLT2‐i versus DPP‐4i. Conclusions: This real‐world data analysis supports reassuring findings from previous randomized clinical trials showing no increased AKI risk among SGLT2‐i users. Nevertheless, because of the more prominent decrease in eGFR in patients with moderate CKD, cautious use of SGLT2‐i in patients with reduced eGFR is advised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 2×
“1 per 1000 patientyears in the canagliflozin and placebo arms, respectively.(3) The renal safety of empagliflozin was also shown in patients with CKD stage 3 in a pooled analysis of >12 000 patients in the drug's development programme.”
BackgroundResultEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 2×
“empagliflozin slowed the progression of diabetic kidney disease and reduced rates of clinically relevant renal events.(2) Similar cardioprotective and renal protective findings have recently been reported with canagliflozin in the CANagliflozin cardioVascular Assessment Study (CANVAS) trial, suggesting the possibility…”
BackgroundResultVallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635 · cited 1×
“Another proposed mechanism is an increase in renal HIF1-α expression, which promotes cellular adaptation to hypoxia.(17) The strength of our study lies in our large cohort of >120 000 patients with diabetes for whom extensive demographic, clinical and laboratory data are available.”
BackgroundMudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571 · cited 1×
“It has also been suggested that the shift in energy substrate utilization from glucose to fatty acid oxidation (ketogenesis) improves mitochondrial efficiency and ATP generation in the kidney.(16) Another proposed mechanism is an increase in renal HIF1-α expression, which promotes cellular adaptation to hypoxia.”
BackgroundCanagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361 · cited 1×
“Similar cardioprotective and renal protective findings have recently been reported with canagliflozin in the CANagliflozin cardioVascular Assessment Study (CANVAS) trial, suggesting the possibility of a class effect.(3,4) However, concern has been raised regarding the possibility of an increased risk of acute renal fa…”
ResultAcute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
Nadkarni, G. N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., Saha, A., Ferket, B., Grams, M. E., & Coca, S. G. (2017) · Diabetes Care · doi:10.2337/dc17-1011 · Cited by 188
Research works printed but not linked: 9
- 10.1056/NEJMra1214243 · DOI · Paper page
- 10.1007/s12325-017-0573-0 · DOI · Paper page
- 10.1111/dom.12917 · DOI · Paper page
- 10.1161/JAHA.117.007165 · DOI · Paper page
- 10.1016/j.numecd.2017.10.011 · DOI
- 10.1111/dom.12654 · DOI · Paper page
- 10.1007/s40620-017-0423-9 · DOI · Paper page
- 10.1056/NEJMcibr1608564 · DOI · Paper page
- 10.14740/jocmr2760w · DOI · Paper page
Cited by
Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684
Self-citationSGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Sridhar, V. S., Rahman, H. U., & Cherney, D. Z. I. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13965 · Cited by 24
“events among patients initiating an SGLT2 inhibitor compared to DPP-4 inhibition.(70) While the mechanisms responsible for reduced AKI risk are not yet known, a variety of hypotheses have been put for-”
Background
Metadata
- Authors
- Cahn, A., Melzer‐Cohen, C., Pollack, R., Chodick, G., & Shalev, V.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-10-15
- Volume
- 21
- Issue
- 2
- Pages
- 340-348
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2890282628
- Cited by
- 85
- References
- 7
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis. https://app.cochat.ai/papers/10.1111/dom.13532
- The paper
- Cahn, A., Melzer‐Cohen, C., Pollack, R., Chodick, G., & Shalev, V. (2019). Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.